Connect with us

Health

China’s 2nd protein subunit COVID-19 vaccine to enter clinical trials, easy to mass produce – Global Times

China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed…

Published

on

Article feature image

Sinopharm’s COVID-19 vaccine. Photo: VCG
China’s COVID-19 protein subunit vaccines have reported encouraging progress as a leading Chinese vaccine producer, Sinopharm, plans to bring its newly developed recombinant subunit vaccine candidate into clinical trials.
Sinopharm’s vaccine is the second protein subunit vaccine in the country after one developed by China’s Anhui Zhifei Longcom Biopharmaceutical Co, which started late-stage trials in Pakistan upon approval on Sunday.
The protein subunit vaccine…

Click here to view the original article.

Continue Reading
Advertisement
Advertisement

Trending